Aprea Therapeutics, Inc. (APRE)
| Previous Close | 0.9793 |
| Open | 0.9750 |
| Bid | 0.9457 x 1200 |
| Ask | 0.9556 x 1400 |
| Day's Range | 0.9552 - 1.0099 |
| 52 Week Range | 0.6200 - 5.6700 |
| Volume | |
| Avg. Volume | 926,943 |
| Market Cap | 20.512M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
BOSTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will participate in a panel discussion on synthetic lethality at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 12:35 p.m. ET. The panel discussion will be hosted by R
- GlobeNewswire
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. (“Atrin”) and reported financial results for the three months ended March 31, 2022. Business Operations Update: On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on
- GlobeNewswire
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months and year ended December 31, 2021 and provided a business update. Fourth Quarter Financial Results Cash and cash equivalents: As of December 31, 2021, the Company had $53.1 million of cash and cash equivalents
